drugset / Trial / NCT01371617
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of IPI-926 in patients with myelofibrosis (MF) (primary myelofibrosis \[PMF\], post-polycythemia vera myelofibrosis \[post-PV MF\], or post-essential thrombocythemia myelofibrosis \[post-ET MF\]).
Timeline
- Start
- 2011-10
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Patidegib | Small molecule | 110 mg | Oral |
| Subject | Patidegib | Small molecule | 130 mg | Oral |
| Subject | Patidegib | Small molecule | 160 mg | Oral |